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ABSTRACT 
Beta-blocker target dosing and tolerability in a dedicated heart failure 
clinic: Charlotte Maxeke Academic Hospital- 2000-2014.         
BACKGROUND: The benefit of Beta-blockers in chronic heart failure with left 
ventricular dysfunction is well established. However, actual use in “real world” 
heart failure patients has been relatively poor. Beta-blockers have generally 
been underused and under-dosed, largely due to perceptions about 
intolerability. Ivabradine, a pure heart rate lowering agent has recently been 
advocated for heart failure patients with elevated heart rates who could not 
tolerate target doses of beta-blockers.  
AIMS: The aim of this study was to document beta-blocker target dosing and 
tolerability in a dedicated heart failure clinic at Charlotte Maxeke 
Johannesburg Academic Hospital and assess the proportion of patients who 
may require Ivabradine therapy.  
METHODS: The records of all patients attending the heart failure clinic 
between 2000-2014 were reviewed. Demographic, clinical and outcome data 
was recorded for 500 patients.  
RESULTS: At their last clinic visit, 489 out of 500 (97.80%) patients were 
taking a beta-blocker. Patients were stratified into categories according to 
guideline target doses, with 59.8% (n=299) achieving ‘target dose’, 28.0% 
(n=140) a ‘moderate’ dose, 5.4% (n=50) receiving ‘low dose’ of beta-blocker 
and 11 patients (2.2%) no dose. Beta-blocker “intolerant” patients numbered 
61(7.6%). Conventional reasons for beta-blocker caution 
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(bronchospasm/breathlessness, syncope, cardiac decompensation, 
hypotension) were found to be rare. Bradycardia was the commonest cause 
of inadequate uptitration. Only 53 patients (10.6%) were deemed to be 
“Ivabradine suitable”.  
CONCLUSIONS: Beta-blockers are well tolerated with perceptions around 
intolerability and concerns about safety largely unsupported by our 
experience. As a consequence, the role for Ivabradine therapy in patients with 
chronic heart failure is limited. 
Key words: Beta-blockers, Heart Failure, Ivabradine 
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CHAPTER 1: PROTOCOL WITH EXTENDED LITERATURE REVIEW 
 
Beta-blocker Target Dosing and Tolerability in a dedicated Heart Failure Clinic –  
Charlotte Maxeke Johannesburg Academic Hospital: 2000-2014 
 
The benefit of beta-blockers in heart failure is well established (1). Major clinical 
trials have consistently shown reduced morbidity and mortality in patients with 
chronic heart failure with left ventricular dysfunction of all causes when beta-
blockers are used (2, 3). These large trials are supported by meta–analyses of 
smaller studies (3, 4). Significant mortality benefit has been demonstrated, with 
some variation of degree within the drug class. In addition to prolonging survival, 
reduction in the need for hospital admission, prevention of dysrhythmia’s, 
improvement in symptoms of heart failure, and control of ventricular rate has been 
repeatedly demonstrated (4). 
 
As a result, beta-blockers have become an established first line, best practice 
treatment in the management of heart failure with reduced left ventricular function. 
This is reflected in the guidelines of major national and international cardiology 
organizations such as the European Society of Cardiology (ESC) and American Heart 
Association (AHA) /American College of Cardiology (ACC) (5). The Heart Failure 
Society of South Africa, a special interest group of the South African Heart 
Association has adopted the ESC guidelines with minor modifications for local 
circumstances (6). Three key trials have influenced the practice guidelines. These 
are the CIBIS II (Cardiac Insuffiency Bisoprolol Study II), COPERNICUS (Carvedilol 
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Prospective Randomised Cumulative Survival) and MERIT – HF ( Metoprolol CR / XL 
Randomised Intervention Trial in Heart Failure) trials (7-9).   
 
The introduction of beta-blockers in these large trials was in addition to 
conventional heart failure treatment, including an angiotensin converting enzyme 
inhibitor (ACEi) / Angiotensin II Receptor Blocker (ARB) in over 90% of patients in 
the trials(10).  
 
In CIBIS II, bisoprolol, a beta-1 selective blocker was assessed.  
In 2647 patients, mainly in Class III failure, bisoprolol or placebo was added to 
current optimized therapy. Early termination of the trial was mandated due to a 
clear and significant reduction in mortality (34%), reduction in sudden death (44%) 
and in heart failure hospitalization (20%) in the beta blocker group(7). 
 
Metoprolol, a beta-1 selective blocker was tested in MERIT-HF.  Metoprolol (slow 
release formulation) or placebo was administered to 3991 patients, mostly with 
Class III failure. Early termination resulted from a major mortality reduction (34%) 
and decreased rate of sudden cardiac death (44%) in the Metoprolol group (8). 
 
Carvedilol was compared to placebo in the COPERNICUS trial of 2289 patients. 
These patients were significantly clinically worse than studied in the other large 
beta blocker trials with Class III/IV heart failure / ejection fraction less than 25% 
enrollment criteria. (9). This was in addition to optimized standard guideline 
treatment for heart failure. COPERNICUS was terminated early due to the large 
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effect of the carvedilol arm on reducing the all cause mortality end point. A 35% 
reduction in total mortality was noted for carvedilol compared to placebo. Notably, 
the annual mortality of the placebo group in COPERNICUS (18.6%) was significantly 
higher than that of either the study placebo groups in MERIT-HF (11.0%) or CIBIS II 
(13.2%). This was due to the more advanced stage of disease enrollment criteria. 
Consequently, although the relative risk reduction was similar in the large studies, 
the sicker nature of the patients in COPERNICUS meant there was greater absolute 
mortality advantage and therefore a lesser number needed to treat(9). 
 
These large trials (nearly 9000 patients in total), have clearly shown a decrease in 
mortality (average of 34% in each trial), decrease in heart failure related 
hospitalization (28-34% relative risk reduction) within one year of introduction of 
treatment(4).  
 
Additional evidentiary support for the use of beta-blockers is gained by SENIORS 
(Study of effects of Nebivolol Intervention on Outcomes and Rehospitalisation in 
Seniors with Heart Failure) and USCS  (the United States Carvedilol Study), and 
meta-analyses of smaller beta-blocker trials, all of which showed similar clinical 
outcomes of varying degree’s (5). 
 
Within the drug class, the major head to head beta-blocker comparison trials 
include the COMET (Carvedilol or Metoprolol European Trial). Treatment with 
Carvedilol was associated with decreased rate of all-cause mortality (primary 
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endpoint) but was not associated with difference in co-primary endpoint of all-cause 
mortality or all-cause hospitalization in patients with congestive heart failure (2) 
 
The use of beta-blockers has unequivocally shown benefit in chronic heart failure 
with reduced left ventricular function across multiple clinically relevant endpoints, 
including sudden death, pump failure, hospital readmission and self-reported 
patient well being(2, 4, 11-13). The inclusion of beta-blockers in best practice 
guidelines is accepted and considered a core treatment modality in the 
management of heart failure with reduced ejection fraction (1).  
 
The full mode of action of beta-blockers in cardiac failure is incompletely 
understood despite decades of research. The postulated benefit of beta-blockers is 
via multiple mechanisms.  The benefits of beta blockade in heart failure accrue 
through several pathophysiological mechanisms, all of which are potentially 
responsive in a dose - dependant fashion (14). The majority of benefit of beta-
blocker use is derived from of beta-1 receptor blockade.  
The deleterious effect of the high plasma catecholamines and increased 
sympathetic activity on the heart in severe left ventricular dysfunction has been well 
described.(14). Possible mechanisms for beta receptor blockade improving survival 
include reduction in arrhythmia’s, anti-ischaemic action, reduction of catecholamine 
injury, decreased pathological cardiac remodeling, improved heart rate variability 
and reducing heart rate (15).  
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It has been suggested that the majority of benefit in the use of beta-blockers is 
mediated via heart rate reduction (16, 17). As a result the effect on heart rate has 
been most scrutinized. Heart rate is an important prognostic factor in heart failure. 
Increased heart rate is a risk factor for cardiovascular mortality and is independent 
of other accepted risk factors and confounding variables. (18)  
 
There is a defined relationship between increased heart rate and mortality in 
studied patients with heart failure (19). The recent large studies in heart failure 
(CIBIS II, COPERNICUS etc.) have sustained this view. The best prognosis in these 
groups was noted in patients with the lowest baseline heart rate and greatest heart 
rate reduction on therapy (20, 21).  
 
The relationship between resting heart rate and clinical outcome was studied in the 
control arm of the BEAUTIFUL trial, in patients with reduced left ventricular 
function and coronary artery disease (22). There was a clear association of heart rate 
with progression of heart failure. In the control arm, where patients had heart rates  
>70 resting heart beats per min (bpm) group had a 34% greater mortality, 53% 
greater hospitalization rate compared to the <70 bpm cohort. Every 5 bpm above 
this was associated with an 8% increased risk of cardiovascular death (22).  
 
 A recent meta-analysis of heart failure trials, revealed that for every 5 bpm 
reduction in heart rate with beta blockade, relative risk of death decreased by 18% 
(17).  However magnitude of heart rate reduction was a better explanatory variable 
than heart rate achieved in this review. In addition, there was no statistical 
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relationship in this and other studies between beta-blocker dosing achieved and the 
magnitude of all-cause mortality reduction (17, 20, 23).  
 
Ivabradine, an If channel antagonist, acting at the sinoatrial node to produce heart 
rate reduction has been the agent that has been extensively investigated in this 
regard.(22, 23) 
 
The multi-centre, multi-country SHIFT trial (Systolic Heart Failure Treatment with If 
Inhibitor Ivabradine Trial), tested Ivabradine in patients with chronic heart failure 
and a Left Ventricular Ejection Fraction <35%. SHIFT randomised 6505 patients with 
a baseline HR >70, in patients already on optimal guideline directed heart failure 
therapy. This included beta-blockers at maximally tolerated doses.(24) 
 
The composite end-point of mortality and cardiovascular associated hospitalization 
was reduced by 18% in the treatment arm (23). However this effect was mostly 
achieved by decreased hospitalization rather than decrease in mortality. The 
outcome of sudden cardiac death wasn’t affected by ivabradine, which lacks the 
attenuating electrophysiological properties of beta blockers (24). 
 
Also, the greatest benefit in terms of outcome was achieved in the subgroups with 
the highest pre-treatment baseline heart rate and those with the greatest heart rate 
reduction. This finding was in keeping with the meta-analysis of beta-blocker trials 
showing an association of magnitude of heart rate reduction and outcome (17). 
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Of note in the SHIFT trial was the lack of achievement of target dosing in the patient 
population selected. The average doses of beta-blockers were substantially lower 
than those used in the clinical trials that showed benefit. Only 23% of the patients 
were at target doses, and less than half (49%) were receiving 50% or more of the 
target doses at enrollment.  The authors of SHIFT argued that low beta-blocker use 
was because of beta-blocker tolerability and that this was consistent with “real 
world experience”(23). However, this has been a consistent point of criticism in 
interpreting the trial outcomes (25, 26). 
 
In the subgroup of patients receiving at least half the recommended maximum dose 
of a beta-blocker (56% of the patients included in the trial), there was no statistically 
significant difference between the Ivabradine and placebo arms in terms of either 
overall mortality or the primary outcome (a non-significant 12% reduction for those 
on at least 50% but less than 100% of the recommended beta-blocker dose 
(P=0.193)) (24). The implication being that additional heart rate reduction in this 
specific group did not lead to significantly improved outcome. A conclusion drawn 
from this was that the pleomorphic effects of beta-blockers were essential to 
mortality reduction beyond solely the effect on reducing heart rate (26). 
Importantly, if beta-blockers can be used optimally in patients with heart failure, 
there may be a very limited role for further heart rate reduction with Ivabradine.  
 
The actual tolerability of beta-blockers has also been extensively investigated, in 
light of the lack of achievement of the target doses in surveys of “real world” 
patients (patients in a clinical setting not enrolled in tightly managed clinical 
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trials)(27, 28). The results of these reviews showed that heart rate reduction was not 
being achieved in most patients treated with beta-blockers (29).  Beta-blockers 
were underused and under-dosed in these heart failure population groups for 
various reasons (30). 
 
In these large international surveys, it has been shown that only 20-40% of heart 
failure patients were taking beta-blockers and the mean dose was half the 
recommended target dose (28, 31). There appeared to be an exaggerated 
perception of risk of adverse events of usage in these heart failure populations. 
 
The surveyed physicians appeared to be reluctant to initiate and/or up-titrate the 
beta-blockers appropriately because of concerns about safety and tolerability.  
Particular subgroups who were under-dosed or did not have beta-blockers initiated 
at all were the elderly, and those with concomitant disorders such as diabetes, 
chronic obstructive pulmonary disease (COPD)(32) and intermittent claudication 
(31).  
 
In reality there are very few patients with heart failure in whom beta-blockers are 
absolutely contraindicated (33). These include asthmatics, AV blocks, and patients 
with beta-blocker intolerance. Only about 3-5% patients in large survey’s have been 
seen to be intolerant, mainly due to hypotension or bradycardia (29).  
 
In certain subgroups of patients with comorbid diseases such as COPD(34), diabetes 
mellitus and peripheral arterial disease in whom beta-blocker usage by clinicians is 
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historically poor, the evidence for benefit versus harm is clearly in favour of use (29). 
This is reflected in the current guidelines(5) .   
 
The elderly also have traditionally been undertreated in terms of initiation and up-
titration of beta-blockers (30). Various studies have looked at the issue. The Cola II 
study stratified heart failure patients into groups above age 70, in 5-year intervals to 
treatment with carvedilol and assessed patient tolerability. Its findings, 
subsequently supported by further evidence in the SENIORS trial (looking at 
patients >70 years old, treated with nebivolol), demonstrated good tolerability (in 
excess of 80%) across all studied age groups (29) .  
 
CIBIS- ELD (Cardiac Insufficiency Bisoprolol Study in Elderly) looked at two of the 
most widely used beta-blockers in heart failure, carvedilol and bisoprolol and 
investigated tolerability in an elderly population as well as reasons for failure to 
achieve target doses (35). It found 69% of patients did not reach target doses, 
however 55% of patients achieved at least half of the target doses (35). 
 
In general local data is sparse regarding beta-blocker use and achievement of target 
doses. In addition reasons for not tolerating beta-blockers in this population has not 
been assessed.  
 
Conclusions from the SHIFT trial may have been overstated (beta blocker 
tolerability, benefit of additional heart rate reduction). If heart failure patients can in 
fact tolerate optimal therapeutic doses of beta-blockers, there may be very little 
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added morbidity and mortality benefit in adding Ivabradine. It is in this light that I 
planned to evaluate beta-blocker tolerability in the heart failure population at 
CMJAH. 
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1.1 Study Objectives: 
The aim of this study is to investigate target dosing and tolerability of beta-blockers 
in a heart failure population at a tertiary public hospital in Johannesburg. 
 
o To determine beta-blocker tolerability and to compare with the rates of 
beta-blocker use in the SHIFT trial, to assess whether the conclusions drawn 
from the SHIFT trial are necessarily applicable to our patient population.  
o To ascertain reasons for beta-blocker intolerance 
o Assess possible predictive comorbidities / clinical correlates for intolerance 
o Determine achievement of target doses of beta-blockers 
o Assess achievement of heart rate reduction and target heart rates 
o Compare with published cohorts from recent international beta-blocker 
trials 
o To document the demographic and clinical profiles of the patients attending 
the heart failure clinic at CMJAH.  
 
This study is relevant to our local context for the following reasons: 
o Demographics of the studied population are substantially different  - there 
were very few non-caucasian enrollee’s in all the large beta-blocker trials. 
o Causes of heart failure are very different in our patient population. The 
majority of patients enrolled in the large trials had ischaemic heart disease as 
the cause of their heart failure. This is not expected to be replicated in our 
patient population.  
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o Comorbidities are expected to be different than previously studied 
populations 
o In general the patient population is expected to be younger than 
international cohorts 
o Socioeconomic status would appear to be substantially different than the 
large European and North American trials. 
 
It is hypothesized that the patients recruited in the SHIFT trial were on inadequate 
doses of beta-blockers and the beneficial effect of Ivabradine is exaggerated. The 
role for Ivabradine may be much narrower than the authors implied. This is relevant 
to our context because Ivabradine is not currently available in the state sector in 
South Africa.  
 
The data generated from this study will be compared to the international literature. 
The local setting of the heart failure population studied may indeed be unique, as 
the patient profile is substantially different. No current local literature exists 
assessing beta-blocker tolerability, reasons for intolerabilty and target dose 
achievement.  
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1.2 Methods: 
 
 Retrospective analysis of the patient population attending the heart failure 
clinic at Charlotte Maxeke Johannesburg Academic Hospital. 
 
 Analysis of variables related to demographics, clinical profile, standard 
treatment, beta-blocker use, tolerability and effect on heart rate. 
 
 Documentation of the clinical records in a standard data collection sheet. 
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1.3    Study design: 
 Retrospective file analysis.  
 The files of the current patients with adequate records attending the heart 
failure clinic at CMJAH will be reviewed.  
 Analysis of clinical response to beta-blocker therapy will be compared with 
published cohorts in various published beta-blocker trials with an emphasis 
on the recent SHIFT trial.  
 
1.4 Study population and sample 
The study population will comprise adult patients attending the heart failure clinic 
at CMJAH. This is a specialized clinic, accepting patients with a confirmed diagnosis 
on a referral basis from the ward of the hospital as well as its referral hospital 
network. Clinic records will be reviewed retrospectively, and will include all patients 
attending the clinic with complete records. 
 
1.5 Inclusion criteria:  
All adult patients attending the heart failure clinic at CMJAH (diagnosed with heart 
failure previously by a clinician at CMJAH or one of its referral hospitals and referral 
notes analysed and accepted by Cardiologists at CMJAH prior to acceptance). 
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1.6 Description of Methods and Techniques Being Used 
Retrospective review of files meeting the inclusion criteria, using a standardized 
data sheet for data collection as attached.  
 
Variables 
 Age 
 Gender  
 Race 
 Date of Diagnosis 
 Follow up Duration (months) 
 Diagnosis (Cause of heart failure) 
o Ischaemic Heart Disease 
o Other 
 Hypertension 
 HIV 
 Peripartum Cardiomyopathy 
 Chemotherapy induced 
 Other 
 Beta-blocker 
o Atenolol 
o Carvedilol 
o Other 
 Dose of beta-blocker acheived 
o Dose 
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o Daily dose  
o % of target dose (per international trial standard) 
 Other medication 
o Angiotensin Converting Enzyme (ACE) 
o Mineralocorticoid Receptor Antagonist 
o Digoxin 
o Statin 
o Hydrallazine 
o Isosorbide Mononitrate 
o Thiazide Diuretic 
o Calcium Channel Blocker  
 Lasix (Furosemide) daily dose 
 Systolic Blood Pressure at baseline  
 Systolic Blood Pressure at last visit 
 6-Minute-Walk-Test at baseline 
 6-Minute-Walk-Test at last visit 
 New York Heart Association Grading at baseline 
 New York Heart Association Grading at last visit 
 Heart Rate at baseline 
 Heart Rate at last visit 
 Heart rate reduction  
 Reasons for non achievement of target dose 
o Syncope / pre-syncope 
o Hypotension 
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o Bradycardia 
o Bronchospasm 
o Intolerant 
o Logistical 
 eGFR (estimated glomerular filtration rate) at baseline 
 eGFR l(estimated glomerular filtration rate ) at last visit 
 Na+ (Sodium) at baseline 
 Na+ (Sodium) at last visit 
 Ejection Fraction at baseline  
 Ejection Fraction a last visit 
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1.7 Ethics 
Application for permission to analyse file records of the Heart Failure was accepted 
by the Human Research Ethics Committee of the University of the Witwatersrand 
(Ethics Approval Number: M140611) 
 
Random study numbers will be allocated to the data entries. The data sheet 
allocation will be kept separate from other materials related to this study. Data 
entries will not include patient names nor file numbers. 
 
1.8 Funding 
Costs associated with the study are funded by the investigator 
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Abstract: 
Beta-blocker target dosing and tolerability in a dedicated heart failure 
clinic.         
Background: The benefit of Beta-blockers in chronic heart failure with left 
ventricular dysfunction is well established. However, actual use in “real world” 
heart failure patients has been relatively poor. Beta-blockers have generally 
been underused and under-dosed, largely due to perceptions about 
intolerability. Ivabradine, a pure heart rate lowering agent has recently been 
advocated for heart failure patients with elevated heart rates who could not 
tolerate target doses of beta-blockers.  
Aims: The aim of this study was to document beta-blocker target dosing and 
tolerability in a dedicated heart failure clinic at Charlotte Maxeke 
Johannesburg Academic Hospital and assess the proportion of patients who 
may require Ivabradine therapy.  
Methods: The records of all patients attending the heart failure clinic between 
2000-2014 were reviewed. Demographic, clinical and outcome data was 
recorded for 500 patients.  
Results: At their last clinic visit, 489 out of 500 (97.80%) patients were taking 
a beta-blocker. Patients were stratified into categories according to guideline 
target doses, with 59.8% (n=299) achieving ‘target dose’, 28.0% (n=140) a 
‘moderate’ dose, 5.4% (n=50) receiving ‘low dose’ of beta-blocker and 11 
patients (2.2%) no dose. Beta-blocker “intolerant” patients numbered 
61(7.6%). Conventional reasons for beta-blocker caution 
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(bronchospasm/breathlessness, syncope, cardiac decompensation, 
hypotension) were found to be rare. Bradycardia was the commonest cause 
of inadequate uptitration. Ultimately only 53 patients (10.6%) were deemed to 
be “Ivabradine suitable”.  
Conclusions: Beta-blockers are well tolerated with perceptions around 
intolerability and concerns about safety largely unsupported by our 
experience. As a consequence, the role for Ivabradine therapy in patients with 
chronic heart failure is limited. 
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Beta-blocker target dosing and tolerability in a dedicated Heart Failure Clinic 
Bolon J, McCutcheon K, Klug E, Smith D & Manga P 
Division of Cardiology, CMJAH & University of the Witwatersrand, Johannesburg 
 
Background 
The benefit of beta-blockers in heart failure is well established(1, 2).1 Major clinical 
trials have consistently shown reduced morbidity and mortality in patients with 
chronic heart failure with left ventricular dysfunction of all causes when beta-
blockers are included in treatment regimens (2).2 As a result, beta-blockers have 
become an established first line, best practice treatment in the management of 
heart failure with left ventricular dysfunction, as reflected in the guidelines of major 
national and international cardiology organizations such as the American Heart 
Association (AHA) /American College of Cardiology (ACC) and European Society of 
Cardiology (ESC) (adopted with minor modification by The Heart Failure Society of 
South Africa, a special interest group of the South African Heart Association)(3, 4)3,4 
 
Despite the documented survival benefit, actual use in “real world” heart failure 
patient groups has been relatively poor(5).5 Numerous reviews and surveys have 
shown that beta-blockers were being underused and under-dosed in these heart 
failure population groups for various reasons(6),6 with only 12-40% of heart failure 
patients tolerating beta-blockers at target doses and the mean doses found to be 
only half the recommended target dose(5, 7).5 Patients outside of large protocol-
driven clinical trials consistently failed to achieve target dose and or target heart 
rate (8). The surveyed physicians demonstrated reluctance to initiate or up-titrate 
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beta-blockers appropriately because of concerns about safety and tolerability (9) 
(10).6 
 
In light of the documented adverse effect on mortality of an elevated heart rate, the 
demonstration of mortality benefit in heart rate reduction therapy, and the 
reluctance of physicians to adequately prescribe and up-titrate beta blockers at 
target dose due to safety concerns, a pure heart rate lowering agent was 
sought(11)7. Ivabradine, a selective If current inhibitor, induces dose-dependent 
heart rate reduction by directly reducing sinoatrial node pacemaker activity. This 
agent has been studied in the seminal SHIFT trial (Systolic Heart Failure Treatment 
with If Inhibitor Ivabradine Trial)(12),8 where 6558 patients with chronic heart failure, 
left ventricular ejection fraction <35%, and a baseline heart rate (HR) >70 were 
randomized to receive  ivabradine or placebo. Patients were already meant to be on 
optimal guideline directed heart failure therapy (including beta-blockers at 
maximally tolerated doses). 
 
The composite end-point of mortality and cardiovascular associated hospitalization 
was reduced by 18% in the treatment arm, driven mostly by decreased 
hospitalization for worsening failure (26%, p<0.0001)(13). However, background 
beta blocker usage was substantially lower in the trial population than 
recommended by the guidelines. Only 23% of the patients were at target doses, and 
less than half (49%) were receiving 50% or more of the target doses at enrollment. 
The authors of the study explained that the low beta blocker was a result of 
standard clinical practice in their larger study population, however criticism of 
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applicability followed(14), since under treatment with beta blockers possibly 
inflated the potential benefit and exaggerated the proposed role of ivabradine as a 
treatment modality. Despite criticism(14) (15) the results of the SHIFT trial have 
resulted in ivabradine being given a Class IIa recommendation for the reduction of 
hospitalization or cardiovascular death in the latest ESC Heart Failure guidelines(3)4 . 
 
In this regard, there remains a paucity of data in South African patients regarding 
the need for further heart rate reduction therapy in patients with heart failure with 
reduced left ventricular function. It is our hypothesis that most heart failure patients 
tolerate guideline-mandated doses of beta-blocker therapy and, if adequately up-
titrated, will not need further rate reduction with agents such as ivabradine. 
 
We thus sought to investigate target dosing and tolerability of beta-blockers in a 
heart failure population at a tertiary public hospital in Johannesburg, South Africa 
and to assess the potential role for additional heart rate lowering agents (such as 
ivabradine) in this heart failure population. 
 
Methods 
Ethics approval for our study was obtained from the Human Research Ethics 
Committee, University of the Witwatersrand. Clinical records of all patients 
attending the Heart Failure Clinic at Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) in the period January 2000 to December 2014 were 
retrospectively reviewed. 
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All adult patients attending the heart failure clinic at CMJAH during this period were 
included. These patients were referred to this specialist clinic with a diagnosis of left 
ventricular systolic heart failure diagnosed by a clinician at CMJAH or a referral 
hospital and confirmed by echocardiography demonstrating LVEF <50%. 
 
Demographic and clinical data was recorded, including data at entry to the clinic 
and at the last recorded visit. 
 
Results 
Five hundred patients fulfilled the inclusion criteria for the study and were included 
in this analysis.  Patients in the clinic are managed according to local and 
international best practice and as part of this, beta blockers are routinely used, 
unless contra-indicated, and judiciously up-titrated to target doses as 
tolerated.  The patients’ characteristics are shown in Table 1. 
 
Male patients comprised 52.5% (n=263) and the mean (SD) age of the cohort was 55 
(15) years. Black patients (66.4%) constituted the predominant ethnic group of the 
study. Hypertensive heart disease was the commonest cause of heart failure 
(32.8%), followed by ischaemic heart disease (22%). Mean (SD) ejection fraction at 
admission to the clinic was 27.3 (8.4)%. 
 
Median follow up duration (first appointment recorded at clinic to last recorded 
visit) was 58.7 months (range: 2-179). At enrollment, 87% of patients (n=436) were in 
sinus rhythm. Mean initial heart rate was 85.9 beats per minute (bpm), with last 
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achieved mean heart rate 71.7 bpm. The majority of patients were on guideline 
based heart failure treatments. For example, 95.8% of patients were using ACE 
inhibitors, and 89.8% of patients were using spironolactone (Table 1). At their last 
clinic visit, 489 patients (97.8%) were taking a beta blocker. Patients were stratified 
into categories according to target doses (Table 2), with 59.8% (n=299) achieving 
target dose, 28.0%(n=140) receiving an intermediate dose and 5.4% (n=50) 
receiving low doses of beta blockers (Figure 1). 
 
Reasons for intolerance, defined as no or low doses (<50% of target dose), and 
reasons for not achieving target dose are detailed in Table 3. Conventional reasons 
for clinician beta blocker caution, such as bronchospasm / breathlessness (n=7; 
1.4%), peripheral arterial disease (n=0), syncope (n=3; 0.6%), cardiac 
decompensation (n=4; 0.8%) and hypotension (n=2; 0.2%) were found to be rare. 
Approximately 10% of patients did not achieve the target dose for logistical reasons 
(enrolled in the uptitration phase or poor treatment adherence), and in 5% (n=25), 
no reason was determined. Bradycardia was the commonest cause of inadequate 
up-titration. However, analysis of the 201 patients who did not achieve the target 
dose, demonstrated that 104 (51.7%) ultimately achieved the target heart rates 
(26/61 (51%) of the nil/low dose group as well as 78/141 (55.3%) of the moderate 
dose group). 
 
There were no statistically significant correlates for intolerance in terms of ethnicity, 
cause of heart failure or presence or absence of concurrent treatments. A history of 
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asthma (p=0.021), and a diagnosis of hypothyroidism (p=0.009) were independently 
correlated with beta blocker intolerance. 
 
Patients were determined to be ivabadrine “suitable” if they were in sinus rhythm, 
with an EF<35% and a resting heart rate of greater than or equal to 70 bpm after 
appropriate up-titration of a beta blocker.  Of the 500 initial patients assessed, 137 
met this criterion (27.4%). Further excluding patients with New York Heart 
Association Class I symptoms, only 53 (10.6%) were deemed ivabadrine “suitable” 
(Figure 2). 
 
The ivabadrine “suitable” subgroup at enrollment had a lower mean ejection 
fraction compared to the larger clinic cohort (EF: 21.0% vs. EF: 27.3%, p=0.0001), as 
well as higher resting heart rates (mean 94.2bpm vs. mean 85.9bpm, p=0.006). In 
addition, this subgroup had a shorter follow up duration (43.3 months vs. 58.7 
months, p=0.006). 
 
Diabetes Mellitus as a diagnosis was correlated with ivabadrine “suitable”(p=0.003), 
with these patients being twice as likely to be suitable (32.7% of suitable subgroup, 
16.1% cohort). Unfortunately no data was captured regarding patients’ long-term 
glycemic control, frequency of hypoglycemic episodes or presence or absence of 
target damage such as autonomic neuropathy. None of patients’ gender, cause of 
heart failure, nor associated treatments were predictive of ivabradine ‘suitable’ 
status. 
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Discussion 
Efficacy of beta blockers in heart failure has been widely established but actual use 
has been unsatisfactory, largely due to perceptions about tolerability and 
consequent reluctance amongst clinicians to up-titrate doses despite widely 
accepted guidelines (5) (9).5 The perceptions of danger and intolerability of beta 
blockers appear to be over exaggerated to the disadvantage of patients who would 
fully benefit. 
 
In this study we have demonstrated that in a dedicated heart failure 
HF clinic in a large public hospital, most (97.8%) heart failure patients can be 
prescribed a beta blocker. Almost 88% of these patients tolerate up-titration of 
their beta blockers to target or intermediate doses. Thus in this “real world” 
population, we have shown that beta blockers were used more often and at much 
higher doses than those reported in recent multi-centre surveys(6, 8). 
 
Furthermore we have shown that in certain subgroups of patients with comorbid 
diseases such as chronic obstructive pulmonary disease (COPD)(16), diabetes 
mellitus and peripheral arterial disease in whom beta-blocker usage by clinicians is 
historically poor (10), the use of beta-blockers is generally safe with a small minority 
unable to tolerate intermediate or target doses. This practice is supported in the 
current guidelines (3, 4). 
 
In the South African context there are no published data regarding beta-blocker 
use, tolerability and achievement of target doses in heart failure patients. In 
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addition, reasons for not tolerating beta-blockers in this population has not been 
assessed previously. Importantly it must be noted that black patients made up 66% 
of our total cohort. There are no published data reflecting the use and tolerability of 
beta blockers in black patients with systolic heart failure. In the SHIFT trial (13), the 
majority of patients were white (89%) with black patients comprising less than 3% 
(grouped in category of “other”). 
 
The socioeconomic status of our clinic patients would appear to be substantially 
different than that in the large European and North American clinical trials (17). 
Significantly, despite the major challenges of this relatively economically poor 
group of patients, the majority of patients were able to be compliant and were up 
titrated successfully. 
 
Patient factors for predicting intolerance appear to be concurrent asthma (but not 
COPD) and hypothyroidism. Bronchospastic disorders are a well described cause for 
traditional clinician reluctance to initiate or uptitrate beta blockers and this 
subgroup of heart failure patients has been traditionally undertreated(18). 
Hypothyroidism (as well as hyperthyroidism) has been noted to be associated with 
an increased risk of mortality in heart failure patients, even after controlling for 
known mortality predictors, however no risk for beta intolerance has been 
previously described(19). 
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It would appear that conclusions from the SHIFT trial are not widely applicable in 
our setting, with its main conclusions being overstated (beta blocker intolerability / 
posited role for additional heart rate reducing agent). 
 
The patient populations studied in SHIFT were broadly similar to our cohort (13). 
However, in our study patients were younger by 5 years (mean age 55.8 vs. 60.1), 
included more females (47% vs. 24%), and were more ethnically diverse. Ischemic 
heart disease was the predominant cause of heart failure in SHIFT (68%), compared 
to 22% in our study (Table 1). Ejection fraction at enrollment was slightly worse in 
our study patients as compared to SHIFT patients (27% vs 29%). Notably mean 
estimated glomerular filtration rate (eGFR, mL/min per 1·73 m2) in our study 
patients was better (85.24 ml/min) compared to SHIFT’s cohort (74.6 ml/min). These 
and possibly other unknown factors may have played a role in the better response 
and tolerance of our patients to beta blockade. 
 
This study demonstrates that beta blockers are well-tolerated in the treatment of 
chronic heart failure. The role of ivabradine in the treatment of patients with heart 
failure remains to be determined. However, our study suggests that it would remain 
a useful but ultimately limited adjunct to current management. Our results suggest 
that the number of ivabadrine “suitable” patients in a dedicated Heart Failure clinic 
in South Africa would be small after deliberate initiation and up-titration of beta 
blockers according to local and international standards. 
  
Conclusion 
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In contrast to large international surveys (5) (9),6 beta blockers were generally well 
tolerated by patients attending a dedicated heart failure clinic at a large urban 
public hospital in South Africa. Despite significant socioeconomic challenges for 
many of these patients, very few were unable to tolerate any dose of beta blocker, 
and the numbers who were ‘intolerant’ to beta blocker therapy were relatively 
small. Compliance was excellent and up-titration to treatment targets was largely 
successful. Our results demonstrate that in real-life clinical practice, beta blockers 
can be used more often and at much higher doses than previous physician 
sentiment suggests. Guideline suggested target doses are largely achievable, and 
tolerability concerns are not significant at all. 
 
As a consequence, the role for additional rate control therapy beyond beta blockers 
in systolic heart failure patients is limited to only a small group of selected patients. 
As the clinical profile of systolic heart failure of our patient cohort is likely to be 
similar in the rest of South Africa and Africa it is therefore likely that the role for 
ivabradine in the treatment of chronic heart failure with left ventricular systolic 
impairment is limited in this region. The posited role for this drug, following from 
the conclusions of the SHIFT Trial, appears to be exaggerated. 
 
 
Beta blockers remain the bedrock of standard of care in systolic heart failure and 
should be actively commenced and up-titrated, with the expectation of achieving 
moderate to optimum dosage in the vast majority of patients. 
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Table 1- Baseline and subgroup patient characteristics 
Variable Baseline Cohort Beta Blocker Intolerant Ivabradine Suitable 
Number 500 61 53 
Age, years 55.28 +-14.94 59.13+-17.29 52.21+-14.74 
Male 263 (52.5%) 33(54.1%) 34(64.15%) 
Follow-up duration, 
months 58.70 =-43.80 59.80+-50.9 43.26+-39.08 
Causes of HF       
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IHD 110 (22%) 17 (27.95%) 14(26.42%) 
HT 164(32.8%) 17 (27.95%) 16(30.19%) 
PPCMO 61(12.2%) 12(19.7%) 1 (1.89%) 
HIV 21(4.2%) 1(1.6%) 4(7.55%) 
Chemo 24 (4.8%) 2(3.3%) 5(9.43%) 
Alcohol / Toxins 24(4.8%) 1(1.6%) 2(3.77%) 
Myocarditis 12(2.4%) 1(1.6%) 0 (0%) 
Idiopathic / Unknown 66(13.2%) 11(18.0%) 11(20.75%) 
Ethnicity       
Black 332 (66.35%) 37 (60.7%) 33(62.6%) 
Indian 32 (6.41%) 6 (9.8%) 6 (11.32%) 
White 124 (24.85%) 18(29.5%) 12 (22.64%) 
Coloured 12 (2.40%) 0 (0%) 2 (3.77%) 
Asian 0 (0%) 0 (0%) 0(0%) 
Atrial Fibrillation 64(13.0%) 7(11.5%) N/A 
SBP mmHg    
Initial 120.75+-20.64 116.82+-20.36 118.61+-14.45 
Last 116.25+-18.31 109.83+-18.44 111.56+-14.55 
NYHA (Initial)       
I 159 (31.8%) 16 (26.2%) N/A 
II 258 (51.6%) 33(54.1%) 37 (69.81%) 
III 78 (15.6%) 13(21.3%) 13(24.52%) 
IV 5 (1.0%) 1(1.6%) 2 (3.77%) 
Weight, initial 78.48 +-17.95 76.37+-19.54 78.05+-16.82 
eGFR, ml/min/1.73 85.24 +-34.26 78.36+-24.03   
HR, bpm       
Initial (n=496) 85.90 +-15.13 82.08+-14.95 94.22+-15.66 
Last (achieved)(n=480) 71.68 +-11.27 71.92+-14.19 80.17+-8.53 
Other Agents       
ACEi 469(93.8%)     
MRA 449(89.8%)     
Cardiac Glycoside 63(12.6%)     
Statin 206(41.2%)     
ISMO 148(29.6%)     
Hydrallazine 72(14.4%)     
Thiazide 73(14.6%)     
CCB 47(9.4%)     
Values are Mean +-SD or n (%) 
IHD, ischaemic heart disease; HT, hypertension; PPCMO, peripartum cardiomyopathy; HIV, human Immunodeficiency virus; NYHA, 
New York Heart Association classification; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; HR, heart rate; 
BPM, beats per minute; ACEi, angiotensin converting enzyme inhibitor; MRA, mineralocorticoid receptor antagonist; ISMO, 
isosorbide mononitrate; CCB, calcium channel blocker 
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Table 3 – Reasons for Not Achieving Beta Blocker Target Dose 
Reason for Not at Target 
No BB 
Group 
Low Dose 
Group 
Moderate Dose 
Group 
Total % (n=500) 
Syncope 1 2 0 3 0,60% 
Hypotension 0 0 1 1 0,20% 
Cardiac Decompensation 0 0 4 4 0,80% 
Raynauds / PAD 0 0 0 0 0,00% 
Bradycardia 6 22 78 106 21,20% 
Bronchospasm /Breathlessness 3 2 2 7 1,40% 
Fatigue 0 3 2 5 1,00% 
Logistical           
Non-Compliance 0 4 12 16 3,20% 
Uptitration phase 1 12 21 34 6,80% 
Unknown 0 5 20 25 5,00% 
Total 11 50 140 201 40,20% 
 
Table 2 – Categorisation of Beta Blocker Dose 
Total Beta Blocker dose (Daily)  
B-Blocker Low Dose Range  Moderate Dose Range Target Dose Range 
Bisoprolol <5mg 5mg to <10mg 10mg 
Carvedilol <25mg 24mg to <50mg 50mg 
Metoprolol <100mg 100mg to <400mg 400mg 
Atenolol <50mg 40mg to <100mg 100mg  
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Figure 1 - Beta Blocker Target Dose Stratification 
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Figure 2 – Relative Proportion of Patients Suitable for Ivabradine 
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Note: 
Turn-it-in report as above 
 Flagged every reference in entirety in both reference lists of the 
extended literature review and the submissable paper 
 Flagged every trial named in the text in their entirety  
e.g. CIBIS II (Cardiac Insuffiency Bisoprolol Study II), COPERNICUS 
(Carvedilol Prospective Randomised Cumulative Survival) and MERIT 
– HF ( Metoprolol CR / XL Randomised Intervention Trial in Heart 
Failure) trials. 
